Doctor of Medicine Proves the Potential of Suilysin Recombinant Protein in the Treatment of Sensorineural Deafness Due to Meningitis Suis

Doctor of Medicine Proves the Potential of Suilysin Recombinant Protein in the Treatment of Sensorineural Deafness Due to Meningitis Suis

 

Located in the meeting room of Dr. A A. Made Djelantik, Faculty of Medicine Unud Building, Denpasar, a Doctoral Promotion exam took place with the promovenda candidate, dr. Tjokorda Istri Pramitasuri, S.Ked., M.Biomed., with the dissertation title "Changes in Levels of Brain-Derived Neurotrophic Factor, Junctional Adhesion Molecule-C, and Myelin Index in the Central Auditory Region in the Brains of BALB/C Mice Induced by Suilysin Recombinant Protein" (10/7/2023)

 

World neuroscientific research related to sensorineural deafness due to S.suis meningitis is currently centered on the identification of pathogenesis mechanisms. Suilysin is the only S.suis virulence factor that is toxic to epithelial cells and has high potential to be a potential vaccine and therapeutic target candidate. The purpose of this study was to determine the role of SLY in causing demyelination of the central auditory region in the brain. The design used in this research is Laboratory Descriptive Explorative Design and True Experimental. The study was carried out for 18 months, starting with the construction of Suilysin recombinant protein (rSLY), followed by dosage determination, intracranial injection of rSLY in BALB/c mice, measurement of Brain-Derived Neurotrophic Factor (BDNF) and Junctional Adhesion Molecule-C (JAM-C) levels. ) by ELISA test, and identification of myelin indexes in the Cochlear Nucleus region, Superior Olivary Complex, Medial Geniculate Nucleus, and Inferior Coliculus in the brains of BALB/c mice by Luxol Fast Blue staining.

 

Before being tested in an open doctoral promotion session, the results of this study were presented at Imperial College London, United Kingdom, under the supervision of Prof. Andrew SC Rice, MD, FRCP, FRCA, FFPMRCA, FFPMCAI in January 2023.

 

The results of this study indicated that the average BDNF level in the control group was significantly higher (p=0.02) than in the Suilysin High Dose (SHD) group. The average JAM-C level in the control group was significantly higher than the SHD and Suilysin Low Dose (SLD) groups, with the largest mean difference found in the control and SHD groups. The myelin index in the four brain regions of mice in the control group was significantly higher than in the SHD group.

 

This research has resulted in the success of making rSLY recombinant protein and intracranial administration of rSLY protein to reduce levels of BDNF, JAM-C, and myelin index in the four central auditory regions of the brain Mus musculus strain BALB/c. The results of this study have the potential to be developed as basic data in future studies regarding SLY as a therapeutic target and neuroprotection for sensorineural deafness after S. suis meningitis.

 

The exam was led by the Dean of FK Unud, Dr. dr. Komang Januartha Putra Pinatih, M.Kes with the testing team:

1. Dr. dr. A A. Raka Sudewi, Sp.S(K) (Promoter)

2. Prof. Dr. drh. I Gusti Ngurah Kade Mahardika (Co-promoter I)

3. dr. Ni Nengah Dwi Fatmawati, Sp.MK., Ph.D (Co-promoter II)

4.Prof. Dr. dr. Dewa Putu Gde Purwa Samatra, Sp.S (K)

5. Prof. Dr. dr. I Made Jawi, M. Kes

6. Prof. Ir. I.B. Putra Manuaba, M.Phill

7. Prof. Dr. dr. A A. Wiradewi Lestari, Sp.PK (K)

8.Dr. dr. Desak Made Wihandani, M.Kes

9.Dr. dr. Ni Putu Sriwidnyani, Sp.PA

 

While academic invitations are:

1.Dr. dr. A A. Ayu Putri Laksmidewi, Sp.S(K)

2.Dr. dr. Ketut Dewi Kumarawati, Sp.A(K)

3.Dr. drh. Hamong Suharsono, M. Kes

4.Dr. dr. I Putu Eka Widyadharma, M.Sc., Sp.S(K)

5.Dr. dr. Ni Made Susilawati, Sp.S(K)

 

In this exam, Dr. dr. Tjokorda Istri Pramitasuri, S.Ked., M.Biomed., was declared a graduate as the 390th Doctoral Graduate of the Doctoral Degree in Medical Sciences, Faculty of Medicine, Udayana University with cum laude predicate.